Chiesi Farmaceutici

Chiesi Farmaceutici: In vivo and longitudinal studies of lung fibrosis using next gen µCT

Chiesi Farmaceutici is committed to the care and improvement of the quality of life of people suffering from respiratory diseases including asthma and COPD (Chronic Obstructive Pulmonary Disease). Asthma and COPD are characterised by a reduction in the respiratory flow although they are driven by a different pathophysiological pathway.

Chiesi Farmaceutici investigates and develops new therapeutic solutions for these diseases based on innovative technology. In collaboration with Phares we performed in vivo and longitudinal studies of lung fibrosis using next generation micro Computed Tomography (µCT) technology. The available low ionizing radiation dose and fast small animal imaging systems allowed accurate analysis of lung tissue compostion and function in our model system.

The most significant information from this µCT analysis was that the increased poorly aerated lung tissue observed in our model is consistent with fibrotic lesions detected by classical histology and that µCT can reliably give 3D information on lung disease changes.

The experiments that were designed in close collaboration with Phares were successfully executed within strict timelines. Concise reporting of the results and direct contact with the executing technicians, staff and management of Phares guaranteed a pleasant atmosphere during all stages of the project.

Fabio Stellari

Chiesi Farmaceutici

2D and 3D μCT lung images (baseline)